[HTML][HTML] New progress in drugs treatment of diabetic kidney disease
J Wang, H Xiang, Y Lu, T Wu, G Ji - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Diabetic kidney disease (DKD) is not only one of the main complications of diabetes, but
also the leading cause of the end-stage renal disease (ESRD). The occurrence and …
also the leading cause of the end-stage renal disease (ESRD). The occurrence and …
Sulodexide for diabetic-induced disabilities: a systematic review and meta-analysis
AA Bignamini, A Chebil, G Gambaro, J Matuška - Advances in Therapy, 2021 - Springer
Introduction Micro-and macrovascular complications of diabetes are leading morbidities in
the world population. They are responsible not only for increased mortality but also severe …
the world population. They are responsible not only for increased mortality but also severe …
Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective
S Das, R Gnanasambandan - Life Sciences, 2023 - Elsevier
A significant portion of the health burden of diabetic kidney disease (DKD) is caused by both
type 1 and type 2 diabetes which leads to morbidity and mortality globally. It is one of the …
type 1 and type 2 diabetes which leads to morbidity and mortality globally. It is one of the …
Protective Role of Sulodexide on Renal Injury Induced by Limb Ischemia‐Reperfusion
T Yuan, N Yang, W Bi, J Zhang, X Li… - Evidence‐Based …, 2021 - Wiley Online Library
Background. Though widely known as a potent antithrombin agent with protective effects on
the kidney and other remote organs, it is currently ambiguous when it comes to sulodexide's …
the kidney and other remote organs, it is currently ambiguous when it comes to sulodexide's …
SULODEXIDE PROTECTS ENDOTHELIAL CELLS AGAINST 4-HYDROXYNONENAL-INDUCED OXIDATIVE STRESS AND GLUTATHIONE-DEPENDENT REDOX …
K Bontor, B Gabryel - Journal of Physiology & Pharmacology, 2024 - search.ebscohost.com
The lipid peroxidation product 4-hydroxynonenal (HNE) may be involved in vascular
endothelial cell damage by induction of oxidative stress, apoptosis, and loss of redox …
endothelial cell damage by induction of oxidative stress, apoptosis, and loss of redox …
葡糖醛酸基葡糖胺聚糖硫酸盐对糖尿病肾病的干预效果
倪晓英, 廖卓君, 冯建勋, 盛骏駸, 徐敏, 刘志文… - 实用临床医药 …, 2021 - jcmp.yzu.edu.cn
葡糖#酸基葡糖胺聚糖硫酸盐对糖+病肾病的干预效ж Page 1 葡糖#酸基葡糖胺聚糖硫酸盐 对糖
+病肾病的干预效ж !"#,$%&,'(),*+,,- .,/01,2 3,456 (上海市徐汇区中心医院肾脏内科,上海,200031) …
+病肾病的干预效ж !"#,$%&,'(),*+,,- .,/01,2 3,456 (上海市徐汇区中心医院肾脏内科,上海,200031) …
[HTML][HTML] 舒洛地特对显性糖尿病肾病治疗作用的回顾性分析
陈玲, 吴小燕, 高苹 - 武汉大学学报(医学版), 2018 - xml-data.org
目的: 探讨舒洛地特对显性糖尿病肾病的治疗作用. 方法: 采用回顾性队列研究,
将入选患者分为对照组和舒洛地特治疗组, 比较两组患者治疗1 年后24 h 尿蛋白(TP/24 h) …
将入选患者分为对照组和舒洛地特治疗组, 比较两组患者治疗1 年后24 h 尿蛋白(TP/24 h) …
Effects of heparin and derivatives on podocytes: An in vitro functional and morphological evaluation
Unfractionated heparin (UFH) and low molecular heparin derivatives (LMWH) display
numerous biological properties in addition to their anticoagulant effects. However, due to the …
numerous biological properties in addition to their anticoagulant effects. However, due to the …
Sulodexide in the treatment of vascular disease: its therapeutic action on the endothelium
K Jarząbek, B Gabryel, T Urbanek - Phlebological Review, 2016 - termedia.pl
Sulodexide (SDX) is a mixture of highly purified glycosaminoglycans (GAGs), consisting of
80% fast-moving heparin (FMH) and 20% dermatan sulfate (DS). Recently it is becoming …
80% fast-moving heparin (FMH) and 20% dermatan sulfate (DS). Recently it is becoming …
ЗАСТОСУВАННЯ СУЛОДЕКСИДУ В КОМПЛЕКСНІЙ ТЕРАПІЇ ХВОРИХ НА АРТЕРІАЛЬНУ ГІПЕРТЕНЗІЮ ІЗ СУПУТНІМ ЦУКРОВИМ ДІАБЕТОМ У РАЗІ …
ОБ Волошина, ЕА Зубок - Одеський медичний журнал, 2024 - journals.onmedu.od.ua
Анотація Мета цього огляду літератури–оцінити ефективність застосування
сулодексиду у комплексному лікуванні хворих на артеріальну гіпертензію із супутнім …
сулодексиду у комплексному лікуванні хворих на артеріальну гіпертензію із супутнім …